Viscoelastic test-based bleeding risk score reliably predicts coagulopathic bleeding in decompensated cirrhosis and ACLF patients
- 1 July 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Hepatology International
- Vol. 14 (4), 597-608
- https://doi.org/10.1007/s12072-020-10036-y
Abstract
Background and aims Coagulopathic bleeding risk prediction is challenging in decompensated cirrhosis (DC) by conventional assays. Viscoelastic tests (VETs) are likely to be more useful for assessing coagulation status in these patients. We investigated whether the VET (Sonoclot) parameters with fibrinogen could predict coagulopathic bleeding in these patients. Patients and methods Coagulation parameters studied in 874 patients [124 compensated cirrhosis (CC), 521 DC, and 229 acute-on-chronic liver failure (ACLF)] and 190 controls. DC patients were enrolled in derivation (n = 266) and validation (n = 255) cohorts. Sonoclot variables [activated clotting time (ACT), clot rate (CR), platelet function (PF), time to peak (TP) and peak amplitude (PA)] and fibrinogen levels were measured. Coagulopathic bleeding was recorded along with 1-year survival. Results DC patients had prolonged ACT (p < 0.001), depressed CR (p = 0.059), reduced PF (p = 0.09), longer TP (p < 0.001) and smaller PA (p < 0.001), compared to CC and controls (p < 0.001 each). In derivation cohort, 32.3% patients had coagulopathic bleeding. Cox regression analysis of derivation cohort revealed; ACT > 190 s, PF < 1.25 and fibrinogen < 1.2 g/l could predict coagulopathic bleeding and were used to develop a bleeding risk score. In validation cohort; this score was comparable, correlated to real events, and had similar bleed free events with time. The score was also useful in predicting bleed in ACLF patients. In DC patients, 1-year mortality was higher those who bled and received transfusions. Conclusion Viscoelasticity-based bleeding risk score using ACT, PF and fibrinogen, predicts coagulopathic bleeding in DC patients and should be useful in rationalizing transfusion of blood products. Graphic abstract We designed a viscoelastic test-based bleeding risk score which is useful in advanced liver disease to predict the coagulation-related bleeding. This figure shows the lower bleeding-free events in advanced cirrhosis with each incremental bleeding risk score.This publication has 28 references indexed in Scilit:
- Point-of-care coagulation monitoring during liver transplantationTrends in Anaesthesia and Critical Care, 2013
- Hemostasis and thrombosis in patients with liver disease: The ups and downsJournal of Hepatology, 2010
- Rebalanced hemostasis in patients with liver disease: evidence and clinical consequencesBlood, 2010
- Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL)Hepatology International, 2008
- Coagulation Monitoring: Current Techniques and Clinical Use of Viscoelastic Point-of-Care Coagulation DevicesAnesthesia & Analgesia, 2008
- Portal hypertension and variceal bleeding-Unresolved issues. Summary of an American Association for the study of liver diseases and European Association for the study of the liver single-topic conferenceHepatology, 2008
- Abnormalities of hemostasis in chronic liver disease: Reappraisal of their clinical significance and need for clinical and laboratory researchJournal of Hepatology, 2007
- Evolving Consensus in Portal Hypertension Report of the Baveno IV Consensus Workshop on methodology of diagnosis and therapy in portal hypertensionJournal of Hepatology, 2005
- Platelet count and function in spontaneous intracerebral hemorrhageJournal of Stroke and Cerebrovascular Diseases, 2003
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999